Receive our newsletter – data, insights and analysis delivered to you
  1. News
February 15, 2019updated 07 Dec 2021 4:34am

FDA clears Tandem Diabetes’ t:Slim X2 insulin pump

The US Food and Drug Administration (FDA) has granted marketing clearance for the Tandem Diabetes Care’s t:Slim X2 insulin pump, which can deliver insulin under the skin in children and adults with diabetes.

The US Food and Drug Administration (FDA) has granted marketing clearance for the Tandem Diabetes Care’s t:Slim X2 insulin pump, which can deliver insulin under the skin in children and adults with diabetes.

The diabetes technology company noted that the t:Slim X2 is the first under the new alternate controller enabled infusion pumps (ACE pumps) category.

It features an interoperable technology that enables use with various components of diabetes therapy systems, which may include an ACE insulin pump and other compatible medical devices such as automated insulin dosing (AID) systems and continuous glucose monitors (CGMs).

“The device delivers insulin at set or variable rates and can digitally connect with other diabetes management devices for automatic communication and to receive drug dosing commands.”

This capability facilitates the tailoring of diabetes management based on individual preferences.

The device delivers insulin at set or variable rates and can digitally connect with other diabetes management devices for automatic communication and to receive drug dosing commands.

FDA commissioner Scott Gottlieb said: “The marketing authorisation of the first ACE insulin pump intended for interoperable use has the potential to aid patients who seek more individualised diabetes therapy systems and opens the door for developers of future connected diabetes devices to get other safe and effective products to patients more efficiently.”

Content from our partners
The added value of Qarad’s multilingual freephone service to their eIFU solution
Small and simple: how medical device manufacturers select materials
Precision wire: The future of bespoke medical treatment

The regulatory agency reviewed t:Slim X2 performance data that showed accurate and reliable dosing of insulin at the rates and volumes programmed by the user.

It also evaluated the capability of the pump to communicate with external devices with suitable reliability, cybersecurity and fail-safe modes.

The FDA is also establishing criteria called special controls that outline requirements for validating the accuracy, reliability, cybersecurity and clinical relevance of ACE infusion pumps.

In addition, the criteria provide information on the type of studies and data needed to demonstrate the acceptable performance of the pumps.

Diabetes is just one of the most prevalent chronic diseases that is seeing an increase in technological treatments for the condition. Some of the latest medical devices for diabetes include high-tech insulin pens, management apps and glucose monitors.

Additional reporting by Charlotte Edwards. 

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU